期刊
EXPERT OPINION ON DRUG SAFETY
卷 13, 期 1, 页码 5-14出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2013.829036
关键词
anidulafungin; cardiac function; caspofungin; echinocandins; micafungin; toxicity
资金
- Astellas Pharma, Inc. [MYCA-10B02]
Background: Unexplained cardiovascular decompensation has been observed during central venous administration of some echinocandins. Objective: The purpose of this study was to assess cardiac toxicity associated with the echinocandins. Methods: Isolated rat hearts (Langendorff model) were perfused with anidulafungin (ANID), caspofungin (CASP), or micafungin (MICA) at exposures of 1, 4, and 10 times therapeutic concentrations. Changes in left ventricular contractility with experimental exposure were compared to control, and histologic and transmission electron microscopy (TEM) examinations of tissue were performed. Results: Mean concentrations of ANID (10 - 80 mu g/ml) and CASP (6 - 48 mu g/ml) were associated with significant decreases in contractility (-77.1 +/- 9.4% and -40.6 +/- 15.6%, respectively; p < 0.05). MICA was associated with an increase in contractility (13.6 +/- 2.8%, p = NS). On TEM, samples exposed to ANID and CASP had enlarged mitochondria and disintegrating myofibrils. Samples exposed to MICA showed some enlarged mitochondria. Conclusion: Mean concentrations of ANID and CASP were associated with statistically significant decreases in left ventricular contractility at concentrations that may be achievable in humans after peripheral administration, while MICA caused no change. TEM studies suggest this may be a result of mitochondrial damage. Caution may be warranted with central administration of these agents to patients with preexisting cardiac dysfunction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据